These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

584 related articles for article (PubMed ID: 30572031)

  • 21. Programmed death ligand 1 testing in non-small cell lung carcinoma cytology cell block and aspirate smear preparations.
    Noll B; Wang WL; Gong Y; Zhao J; Kalhor N; Prieto V; Staerkel G; Roy-Chowdhuri S
    Cancer Cytopathol; 2018 May; 126(5):342-352. PubMed ID: 29499101
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Update on Immunohistochemical Analysis in Breast Lesions.
    Peng Y; Butt YM; Chen B; Zhang X; Tang P
    Arch Pathol Lab Med; 2017 Aug; 141(8):1033-1051. PubMed ID: 28574279
    [TBL] [Abstract][Full Text] [Related]  

  • 23. p40 & thyroid transcription factor-1 immunohistochemistry: A useful panel to characterize non-small cell lung carcinoma-not otherwise specified (NSCLC-NOS) category.
    Walia R; Jain D; Madan K; Sharma MC; Mathur SR; Mohan A; Iyer VK; Kumar L
    Indian J Med Res; 2017 Jul; 146(1):42-48. PubMed ID: 29168459
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Analytical validation of automated multiplex chromogenic immunohistochemistry for diagnostic and predictive purpose in non-small cell lung cancer.
    Ilié M; Beaulande M; Long-Mira E; Bontoux C; Zahaf K; Lalvée S; Hamila M; Benzaquen J; Cohen C; Berthet JP; Marquette CH; Lassalle S; Hofman V; Hofman P
    Lung Cancer; 2022 Apr; 166():1-8. PubMed ID: 35134710
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rediscovering immunohistochemistry in lung cancer.
    La Salvia A; Meyer ML; Hirsch FR; Kerr KM; Landi L; Tsao MS; Cappuzzo F
    Crit Rev Oncol Hematol; 2024 Aug; 200():104401. PubMed ID: 38815876
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Subtyping of non-small cell lung carcinoma: a comparison of small biopsy and cytology specimens.
    Sigel CS; Moreira AL; Travis WD; Zakowski MF; Thornton RH; Riely GJ; Rekhtman N
    J Thorac Oncol; 2011 Nov; 6(11):1849-56. PubMed ID: 21841504
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of thyroid transcription factor-1 expression by 2 monoclonal antibodies in pulmonary and nonpulmonary primary tumors.
    Matoso A; Singh K; Jacob R; Greaves WO; Tavares R; Noble L; Resnick MB; Delellis RA; Wang LJ
    Appl Immunohistochem Mol Morphol; 2010 Mar; 18(2):142-9. PubMed ID: 19887917
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of Different Antibody Clones for Immunohistochemistry Detection of Programmed Cell Death Ligand 1 (PD-L1) on Non-Small Cell Lung Carcinoma.
    Parra ER; Villalobos P; Mino B; Rodriguez-Canales J
    Appl Immunohistochem Mol Morphol; 2018 Feb; 26(2):83-93. PubMed ID: 28719380
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Using protein microarray technology to screen anti-ERCC1 monoclonal antibodies for specificity and applications in pathology.
    Ma D; Baruch D; Shu Y; Yuan K; Sun Z; Ma K; Hoang T; Fu W; Min L; Lan ZS; Wang F; Mull L; He WW
    BMC Biotechnol; 2012 Nov; 12():88. PubMed ID: 23171216
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunostaining in lung cancer for the clinician. Commonly used markers for differentiating primary and metastatic pulmonary tumors.
    Carney JM; Kraynie AM; Roggli VL
    Ann Am Thorac Soc; 2015 Mar; 12(3):429-35. PubMed ID: 25700114
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Accuracy of classifying poorly differentiated non-small cell lung carcinoma biopsies with commonly used lung carcinoma markers.
    Zachara-Szczakowski S; Verdun T; Churg A
    Hum Pathol; 2015 May; 46(5):776-82. PubMed ID: 25776027
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Difficulties in diagnostics of lung tumours in biopsies: an interpathologist concordance study evaluating the international diagnostic guidelines.
    Ericson Lindquist K; Ciornei C; Westbom-Fremer S; Gudinaviciene I; Ehinger A; Mylona N; Urdar R; Lianou M; Svensson F; Seidal T; Haglund F; Dobra K; Béndek M; Bardóczi E; Szablewska A; Witkowski M; Ramnefjell M; De Las Casas LE; Gulyas M; Hegedus A; Micke P; Brunnström H
    J Clin Pathol; 2022 May; 75(5):302-309. PubMed ID: 33547095
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Does immunohistochemistry affect response to therapy and survival of inoperable non-small cell lung carcinoma patients? A survey of 145 stage III-IV consecutive cases.
    Pelosi G; Haspinger ER; Bimbatti M; Leone G; Paolini B; Fabbri A; Tamborini E; Perrone F; Testi A; Garassino M; Maisonneuve P; de Braud F; Pilotti S; Pastorino U
    Int J Surg Pathol; 2014 Apr; 22(2):136-48. PubMed ID: 24326823
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Interpathologist Diagnostic Agreement for Non-Small Cell Lung Carcinomas Using Current and Recent Classifications.
    Funkhouser WK; Hayes DN; Moore DT; Funkhouser WK; Fine JP; Jo H; Nikolaishvilli-Feinberg N; Eeva M; Grilley-Olson JE; Banks PM; Graziano P; Boswell EL; Elmberger G; Raparia K; Hart CF; Sholl LM; Nolan NJ; Fritchie KJ; Pouagare E; Allen TC; Volmar KE; Biddinger PW; Kleven DT; Papez MJ; Spencer DV; Rekhtman N; Mino-Kenudson M; Hariri L; Driver B; Cagle PT
    Arch Pathol Lab Med; 2018 Dec; 142(12):1537-1548. PubMed ID: 29708428
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Report From the International Society of Urological Pathology (ISUP) Consultation Conference on Molecular Pathology of Urogenital Cancers V: Recommendations on the Use of Immunohistochemical and Molecular Biomarkers in Penile Cancer.
    Canete-Portillo S; Velazquez EF; Kristiansen G; Egevad L; Grignon D; Chaux A; Cubilla AL
    Am J Surg Pathol; 2020 Jul; 44(7):e80-e86. PubMed ID: 32235153
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Utility of a novel triple marker (combination of thyroid transcription factor 1, Napsin A, and P40) in the subclassification of non-small cell lung carcinomas using fine-needle aspiration cases.
    Sharma R; Wang Y; Chen L; Gurda GT; Geddes S; Gabrielson E; Askin F; Li QK
    Hum Pathol; 2016 Aug; 54():8-16. PubMed ID: 27045515
    [TBL] [Abstract][Full Text] [Related]  

  • 37. ΔNp63 (p40) distribution inside lung cancer: a driver biomarker approach to tumor characterization.
    Pelosi G; Rossi G; Cavazza A; Righi L; Maisonneuve P; Barbareschi M; Graziano P; Pastorino U; Garassino M; de Braud F; Papotti M
    Int J Surg Pathol; 2013 Jun; 21(3):229-39. PubMed ID: 23486764
    [TBL] [Abstract][Full Text] [Related]  

  • 38. p40/PD-L1 and TTF1/PD-L1 Immunohistochemical Double Staining Contributes to Intraindividual Variability Associated With PD-L1 Staining Interpretation in Lung Cancer Samples.
    Campelos S; Polónia A; Caramelo A; Curado M; Eloy C
    Appl Immunohistochem Mol Morphol; 2022 Mar; 30(3):165-170. PubMed ID: 35262521
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Programmed Death-Ligand 1 Immunohistochemistry Testing: A Review of Analytical Assays and Clinical Implementation in Non-Small-Cell Lung Cancer.
    Büttner R; Gosney JR; Skov BG; Adam J; Motoi N; Bloom KJ; Dietel M; Longshore JW; López-Ríos F; Penault-Llorca F; Viale G; Wotherspoon AC; Kerr KM; Tsao MS
    J Clin Oncol; 2017 Dec; 35(34):3867-3876. PubMed ID: 29053400
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Quantitative and qualitative characterization of Two PD-L1 clones: SP263 and E1L3N.
    Smith J; Robida MD; Acosta K; Vennapusa B; Mistry A; Martin G; Yates A; Hnatyszyn HJ
    Diagn Pathol; 2016 May; 11(1):44. PubMed ID: 27189072
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.